847446-88-2

Upstream product

• 65753-47-1 2-chloro-3-trifluoromethyl-pyridine 
• 99768-12-4 4-methoxycarbonylphenylboronic acid 
• 87199-17-5 4-formylphenylboronic acid, 
• 847446-85-9 4-(3-(trifluoromethyl)pyridin-2-yl)benzaldehyde 

Downstream Products

• 1056971-06-2 4-(3-trifluoromethyl-pyridin-2-yl)-benzoyl chloride hydrochloride 
• 864372-65-6 N-{4-tert-butyl-3-[2-(tert-butyl-dimethyl-silanyloxy)-ethoxy]-phenyl}-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide 
• 1282032-76-1 4-(3-(trifluoromethyl)pyridin-2-yl)-N-(4-(trimethylsilyl)phenyl)benzamide 

Relevant academic research and scientific papers

Benzoimidazole derivatives and pharmaceutical composition comprising the same

Disclosed herein are novel benzoimidazole derivatives functioning as antagonists to vanilloid receptor-1, and a pharmaceutical composition comprising the same. They are useful in preventing or treating pain, acute pain, chronic pain, neuropathic pain, pos

AMIDE COMPOUNDS AS ION CHANNEL LIGANDS AND USES THEREOF

Compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.

Biarylcarboxybenzamide derivatives as potent vanilloid receptor (VR1) antagonistic ligands

Seventeen biarylcarboxybenzamide derivatives were prepared for the study of their agonistic/antagonistic activities to the vanilloid receptor (VR1) in rat DRG neurons. The replacement of the piperazine moiety of the lead compound 1 with phenyl ring showed quite enhanced antagonistic activity. Among the prepared derivatives, N-(4-tert-butylphenyl)-4-pyridine-2-yl-benzamide (2, IC 50 = 31 nM) and N-(4-tert-butylphenyl)-4-(3-methylpyridine-2-yl) benzamide (3g, IC50 = 31 nM), showed 5-fold higher antagonistic activity than 1 in 45Ca2+-influx assay.